Basic Information
Breye Therapeutics is a clinical-stage biopharmaceutical company headquartered in Denmark, dedicated to developing novel oral therapies for retinal vascular diseases. The company is advancing de-risked, safe, and innovative small molecules suitable for oral administration, with strong scientific rationale for treating conditions such as diabetic retinopathy (DR) and age-related macular degeneration (AMD).